Cargando…

Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case

INTRODUCTION: Apalutamide is a new second‐generation anti‐androgen agent approved in 2019 for the treatment of metastatic, castration‐sensitive, and non‐metastatic, castration‐resistant prostate cancer. We herein report a case of apalutamide‐induced interstitial lung disease. CASE PRESENTATION: A 74...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirishima, Fumiaki, Shigematsu, Yoshinori, Kobayashi, Kanao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741/ https://www.ncbi.nlm.nih.gov/pubmed/35509772 http://dx.doi.org/10.1002/iju5.12420

Ejemplares similares

Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
por: Yuasa, Takeshi
Publicado: (2022)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
por: Belderbos, Bodine P. S. I., et al.
Publicado: (2018)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
por: Chung, Byung Ha, et al.
Publicado: (2021)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature
por: Flynn, Calvin R., et al.
Publicado: (2023)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
por: Miyake, Hideaki, et al.
Publicado: (2023)

Hypothyroidism caused by apalutamide
por: Daviduck, Quinn, et al.
Publicado: (2023)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
por: Smith, Matthew R., et al.
Publicado: (2016)

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
por: Min, Byung-Dal, et al.
Publicado: (2012)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
por: Eberli, Daniel, et al.
Publicado: (2022)

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2021)

Apalutamide‐associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy
por: Tohi, Yoichiro, et al.
Publicado: (2021)

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer
por: Honda, Tomoko, et al.
Publicado: (2022)

Psoriatic Skin Lesions after Apalutamide Treatment
por: MIYAGAWA, Fumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5764o23ih0e2v9uqtu4gr8vcu